ReNeuron Group plc Capital Markets Event (3433O)
May 17 2018 - 2:00AM
UK Regulatory
TIDMRENE
RNS Number : 3433O
ReNeuron Group plc
17 May 2018
17 May 2018 AIM: RENE
ReNeuron Group plc
("ReNeuron" or the "Company")
Capital Markets Event
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the
development of cell-based therapeutics, is today, as previously
announced, hosting a capital markets event focused on the Company's
exosome nanomedicine platform.
ReNeuron is a leader in the field of exosome therapeutics; this
capital markets event will provide an opportunity for attendees to
learn more about the continued progress being made in the Company's
exosome therapy programme, which is based on exosomes secreted by
the Company's proprietary CTX stem cell line.
The Company recently presented positive pre-clinical data at the
ISCT 2018 conference in Montreal, Canada, demonstrating for the
first time that its exosome therapy candidate, ExoPr0, induces
apoptosis (cell death) and/or senescence (arresting of cell growth)
in a number of cancer cell lines and that ExoPr0 significantly
reduces tumour volume in a variety of in vivo xenograft models of
cancer. Dr Randolph Corteling, Head of Research at ReNeuron, will
summarise these positive results at today's event.
The event will take place at 2.30pm today at the offices of
Buchanan, 107 Cheapside, London EC2V 6DN. The Company will not be
providing any new material information.
Webcast details
To access a webcast of the event, please log on to the following
web address approximately 10 minutes before 2.30pm:
http://vm.buchanan.uk.com/2018/reneuron170518/registration.htm
A recording of the presentation will be made available on
ReNeuron's website, www.reneuron.com.
ENDS
ENQUIRIES:
ReNeuron +44 (0)20 3819 8400
Olav Hellebø , Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan +44 (0) 20 7466 5000
Mark Court, Sophie Wills, Tilly Abraham
Stifel Nicolaus Europe Limited +44 (0) 20 7710 7600
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)
N+1 Singer Advisory LLP +44 (0) 20 7496 3000
Mark Taylor (Joint Broker)
About ReNeuron
ReNeuron is a leading, clinical-stage cell therapy development
company. Based in the UK, its primary objective is the development
of novel cell-based therapies targeting areas of significant unmet
or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop
cell-based therapies for significant disease conditions where the
cells can be readily administered "off-the-shelf" to any eligible
patient without the need for additional immunosuppressive drug
treatments. The Company has therapeutic candidates in clinical
development for disability as a result of stroke and for the
blindness-causing disease, retinitis pigmentosa.
ReNeuron is also advancing its proprietary exosome technology
platform as a potential new nanomedicine targeting cancer and as a
potential delivery system for drugs that would otherwise lack
adequate capacity to penetrate to their site of action.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. Further information on ReNeuron and its products can
be found at www.reneuron.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCAFMFTMBJBBAP
(END) Dow Jones Newswires
May 17, 2018 02:00 ET (06:00 GMT)
Reneuron (LSE:RENE)
Historical Stock Chart
From Apr 2024 to May 2024
Reneuron (LSE:RENE)
Historical Stock Chart
From May 2023 to May 2024